Gilead Sciences (NASDAQ:GILD) Trading Up 0.3%

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) were up 0.3% on Friday . The company traded as high as $70.66 and last traded at $70.18. Approximately 717,956 shares changed hands during trading, a decline of 90% from the average daily volume of 7,465,747 shares. The stock had previously closed at $69.97.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on GILD shares. Royal Bank of Canada reiterated a “sector perform” rating and set a $74.00 target price on shares of Gilead Sciences in a report on Monday, July 1st. Oppenheimer reiterated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a report on Monday. Maxim Group cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research note on Wednesday, April 24th. Twelve investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and an average price target of $84.00.

Gilead Sciences Trading Up 0.6 %

The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The firm has a market cap of $87.70 billion, a P/E ratio of 194.94, a P/E/G ratio of 2.92 and a beta of 0.18. The company’s 50 day simple moving average is $66.32 and its 200-day simple moving average is $71.87.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.37 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.38%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after acquiring an additional 2,910,147 shares in the last quarter. Capital World Investors lifted its stake in Gilead Sciences by 1.4% in the 1st quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company’s stock valued at $6,189,435,000 after buying an additional 1,133,281 shares in the last quarter. Capital Research Global Investors lifted its stake in Gilead Sciences by 2.7% in the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock valued at $4,486,296,000 after buying an additional 1,589,240 shares in the last quarter. Wellington Management Group LLP lifted its stake in Gilead Sciences by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after buying an additional 2,350,550 shares in the last quarter. Finally, Norges Bank purchased a new position in Gilead Sciences in the 4th quarter valued at about $1,301,624,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.